• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
CHENG Wenjing,LIU Yi,XU Bilian,LI Wende.Pathogenesis and drug selection in ankylosing spondylitis[J].Journal Of Pharmaceutical Research,2026,45(4):416-423,433[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2346times   Download 1165次 QR Code for this article
Scan with your phone!
强直性脊柱炎的发病机制与药物选择
成文静1,刘义1,许碧莲1,李文德2
Font:Larger+|Default|Smaller-
(1.广东医科大学热带与海洋医学学院,广东 湛江 524023;2.广东省生物技术研究院<广东省实验动物监测中心>,广东 广州 510663)
摘要:
强直性脊柱炎(ankylosing spondylitis,AS)累及骶髂关节与脊柱,多见于年轻男性,症状为腰背痛、晨僵、活动受限。病因受遗传、免疫失衡及肠道菌群多因素驱动。现药物治疗以非甾体类抗炎药(NSAIDs)、肿瘤坏死因子α(TNF-α)抑制剂为主,辅以缓解病情抗风湿药(DMARDs)与糖皮质激素,但疗效与耐受性有限。本文综述发病机制,并附机制图,重点评述白细胞介素-17(IL-17)、IL-23/IL-12、JAK抑制剂、以及成骨通路抑制剂、肠道调节剂及小分子药物的疗效与安全性,供新策略与临床应用参考。
关键词:  强直性脊柱炎  免疫通路  肠道调节剂  综合发病机制  治疗药物  疗效与安全性
DOI:10.13506/j.cnki.jpr.2026.04.009
基金项目:国家自然科学基金项目(No.32470567);广东省自然科学基金面上项目(No.2023A1515010470);广东省科技计划平台项目(No.2021B1212060002);广东省自然科学基金青年基金项目(No.2023A1515111103);广州市科技计划项目(No.2023B03J1257)
Received Date:September 21, 2025   Revision Date:December 15, 2025   Publication Date:April 30, 2026
Pathogenesis and drug selection in ankylosing spondylitis
CHENG Wenjing1,LIU Yi1,XU Bilian1,LI Wende2
(1.College of Tropical and Marine Medicine,Guangdong Medical University,Zhanjiang 524023,China;2.Guangdong Provincial Biotechnology Research Institute,Guangzhou 510663,China)
Abstract:
Ankylosing spondylitis (AS) involves the sacroiliac joints and spine, and is more common in young men. Symptoms include lower back pain, morning stiffness, and limited mobility. The etiology is driven by multiple factors including genetics, immune imbalance, and gut microbiota. The current drug therapy mainly uses NSAIDs and TNF -αinhibitors, supplemented by DMARDs and glucocorticoids, but the efficacy and tolerability are limited. This article provides an overview of the pathogenesis and includes a machine chart, with a focus on the efficacy and safety of IL-17, IL-23/IL-12, JAK inhibitors, osteogenic pathway inhibitors, intestinal modulators, and small molecule drugs, for reference in new strategies and clinical applications.
Key words:  Ankylosing spondylitis  Immune pathways  Intestinal modulators  Comprehensive pathgenesis  Therapeutic drugs  Efficacy and safety
Today's Visits:527    Total Visits:2383269
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.